PRODUCT INFORMATION



CD40 Ligand Chimeric Monoclonal Antibody (Clone IDEC-131 (Toralizumab))

Item No. 37156

Overview and Properties

This vial contains 200 µg of protein A-affinity purified monoclonal antibody. Contents: Synonyms: CD154, CD40L, T-B Cell-activating Molecule, T Cell Antigen Gp39, TNF Ligand

Superfamily Member 5, TNF-related Activation Protein

Immunogen: Recombinant human CD40L

Cross Reactivity: (+) CD40L Species Reactivity: (+) Human P29965 **Uniprot No.:** Form: Liquid

-20°C (as supplied) Storage:

Stability: ≥1 year

PBS with 0.02% ProClin™ 300 Storage Buffer: IDEC-131 (Toralizumab) Clone: Host: Chimeric Monoclonal Antibody

Isotype:

Immunofluorescence (IF); block; the optimal working concentration/dilution should be Application:

determined empirically.

Description

CD40 ligand (CD40L) is a type II transmembrane protein and member of the TNF superfamily encoded by CD40LG in humans. It is expressed primarily by activated T cells, as well as activated B cells and platelets and, under inflammatory conditions, can be induced in natural killer (NK) cells, mast cells, basophils, and monocytes. CD40L trimerizes to engage its receptor, CD40, on various cells, including B cells, dendritic cells, monocytes, platelets, macrophages, endothelial cells, and myoblasts, to induce cell type-specific signaling and activities. Soluble CD40L (sCD40L) is produced by proteolytic cleavage of CD40L at the cell surface and is found in the circulation.^{2,3} sCD40L retains its ability to trimerize and bind to CD40, indicating CD40L can act as a cytokine.3 CD40L stimulates the proliferation of, and increases IgE secretion in, isolated human tonsil B cells. Immune complexes targeting CD40L induce thrombocytopenia and thrombosis in transgenic mice expressing the gene encoding the human IgG receptor (FCGR2A).⁵ Mutations in CD40LG are associated with X-linked immunodeficiency with hyper-IgM (HIGMX-1), a disorder characterized by an immunoglobulin isotype switch defect, increased serum IgM levels, ineffective T cell-B cell cooperation, and recurrent bacterial infections.⁶ Cayman's CD40 Ligand Chimeric Monoclonal Antibody (Clone IDEC-131 (Toralizumab)) was produced recombinantly from the original gp39/CD40 antibody sequence and can be used for immunofluorescence (IF). The gp39/CD40 antibody was generated by immunizing mice with a soluble fusion protein of human gp39-CD8.

References

- 1. Elgueta, R., Benson, M.J., de Vries, V.C., et al. Immunol. Rev. 229(1), 152-172 (2009).
- 2. van Kooten, C. and Banchereau, J. J. Leukoc. Biol. 67(1), 2-17 (2000).
- 3. Doublier, S., Zennaro, C., Musante, L., et al. PLoS One 12(11), e0188045 (2017).
- Spriggs, M.K., Armitage, R.J., Strockbine, L., et al. J. Exp. Med. 176(6), 1543-1550 (1992).
- Robles-Carrillo, L., Meyer, T., Hatfield, M., et al. J. Immunol. 185(3), 1577-1583 (2010).
- 6. Macchi, P., Villa, A., Strina, D., et al. Am. J. Hum. Genet. 56(4), 898-906 (1995).
- 7. Black, A., Hanna, N., Padlan, E.A., et al. Humanized antibodies to human GP39, compositions containing thereof. Idec Pharmaceuticals Corporation. US006001358A (1992).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 02/07/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM